Clinic Events Patient-Centered Physicals 
Annals of Family Medicine
NOVEMBER 20, 2024
Objective The PORTRAIT Registry tracked 797 patients with new or worsening PAD symptoms at vascular specialty clinics and highlighted the underutilization of prevention services and significant disparities in quality of life among women, non-white patients, and those with financial barriers.
Physician's Weekly
JUNE 16, 2025
from MedStar Union Memorial Hospital in Baltimore, and colleagues retrospectively identified and evaluated 130 ankles from 122 patients with a mean follow-up of 5.9 years after primary TAA to examine implant survivorship and clinical and radiographic outcomes. percent) had adverse events, with medial gutter debridement (22 ankles; 16.9
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
GeriPal
JANUARY 23, 2025
Today, we explore four fascinating studies highlighting innovative approaches to reducing medication use and improving patient outcomes. Patients received brochures detailing the risks of gabapentinoids, nonpharmacologic alternatives, and a proposed deprescribing regimen (see here for the brochure ). in the usual care group.
GeriPal
OCTOBER 13, 2022
When I’m on service these days there is inevitably a moment when a resident says “Patient so-and-so is on X” – and I have absolutely no idea what X is. Alex: And we are delighted to welcome Rasheeda Hall, who is a physician scientist in the division of nephrology at Duke University School of Medicine, and sees patients at the Durham VA.
FDA Law Blog
JANUARY 12, 2025
Background on Accelerated Approval The key concept, an ingenuity of FDA itself that has been around since the beginning of accelerated approval, is to allow earlier access to a promising therapy for a serious condition with an unmet medical need based on an endpoint that is reasonably likely to predict clinical benefit.
FDA Law Blog
NOVEMBER 1, 2023
Regulating LDTs: A Long and Winding Road In what might sound to some like protesting too much, the PR invokes FDA’s longstanding assertion that IVDs “manufactured” by laboratories are medical devices and that clinical laboratories that develop tests are acting as manufacturers. FDA’s position is, however, only one side of the story.
GeriPal
DECEMBER 2, 2022
She directs UCSF MERI’s patient, family, and clinician support with classes and consultation on resiliency, well-being, and grief. You wrote about how when it comes to talking about patients with dementia, they’re rarely portrayed as resilient. And the person with dementia, the patient, said yes. How do we move on?
Expert insights. Personalized for you.
130 
Let's personalize your content